Washington DC Set to Expand the Use of ContraPest

PHOENIX, June 8, 2020 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today that the District of Columbia will be rapidly scaling deployment of the Company's ContraPest product. The decision follows a multi-month pilot program in which ContraPest showed efficacy in reducing rat populations in conjunction with an integrated pest management program deployed by DC Health.   

"SenesTech understands the challenges of controlling rat populations for communities like Washington, DC," says Ken Siegel, CEO of SenesTech. "We believe results from the pilot program in cooperation with DC Health demonstrated the value of fertility management in reducing rat populations. We are pleased to support DC Health to scale their program to additional neighborhoods throughout the District."

"As the District enters each phase of re-opening due to the coronavirus (COVID-19) pandemic, there is a risk for the sudden surge of food in restaurant districts and parks which could lead to growing rat problems," says Gerard Brown, Program Manager for DC Health's Rodent and Vector Control Division. "The results from our ongoing pilot program with ContraPest is encouraging and gives me confidence that an expanded deployment can help DC Health control this risk."

Dr. Steve Krause, EVP of Sales and Marketing commented, "A four month study using videography showed rat populations declined between 51-88% in the sites where ContraPest was deployed. We are extremely excited to be able to contribute to the success of our partnership with DC Health through an expanded deployment. We believe ContraPest when used within an integrated pest management program can help municipalities achieve their long-term, sustainable goals for rodent control."

To help the District scale rapidly, SenesTech is providing approximately 4,500 tanks of ContraPest on a complimentary basis and Pestmaster Services, SenesTech's local distributor, will be providing storage and has offered deployment assistance. Dr. Krause remarked, "We want to help Washington, DC get ahead of the potential surge as quickly as possible. Since they were willing to be an earlier adopter of our product, we feel that this is our way of giving back in a time of crisis."

About SenesTech 

SenesTech is changing the model for pest management by targeting one of the root causes of the problem: reproduction.

ContraPest® is an innovative technology with an approach that targets the reproductive capabilities of both sexes in rat populations, inducing egg loss in female rats and impairing sperm development in males. Using a proprietary bait delivery method, ContraPest® is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rat communities. ContraPest® is designed, formulated and dispensed to be low hazard for handlers and non-target species such as wildlife, livestock and pets, where the active ingredients break down rapidly.

We believe ContraPest® will establish a new paradigm in rodent control, resulting in a decreased reliance on lethal options. For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. Forward looking statements include, but are not limited to, our expectation regarding sales commitments, our expectation regarding the conversion of sales commitments and programs to revenue, our belief that our product is more humane, less harmful to the environment and more effective than traditional methods, and our belief that ContraPest will establish a new paradigm in rodent control without environmental effects of rodenticides.  All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT: 

Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.com

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

SOURCE SenesTech, Inc.